EGFR and metastatic malignant neoplasm in the lymph nodes: For instance, in specific treatment subgroups (e.g., EGFR-TKI treatment group), male patients exhibited worse prognoses, and in certain clinical stages (e.g., early-stage lymph node metastasis, absence of distant metastasis, no brain metastasis, or those undergoing surgery), male patients also had a higher mortality risk.